文献速递免疫规划传染病防控与疫情报告

2016-2019年智利儿童患者脑膜炎奈瑟菌全基因组测序及疫苗覆盖预测

Whole-genome sequencing of Neisseria meningitidis collected in Chile from pediatric patients during 2016-2019 and coverage vaccine prediction.
PubMed 文献 · Vaccine · 2024-09-13

对2016-2019年智利儿童患者分离的42株脑膜炎奈瑟菌进行全基因组测序,用MenDeVAR和gMATS工具预测疫苗覆盖。菌株以MenB(25株)和MenW(16株)为主,cc11和cc41/44最常见。MenDeVAR预测4CMenB对MenB菌株完全匹配8%、交叉反应12%、未覆盖8%、数据不足64%;gMATS预测覆盖16%、未覆盖8%、不可预测76%、总体覆盖54%。rLP2086-fHbp对MenB的MenDeVAR预测完全匹配8%、交叉反应64%、数据不足28%、总体覆盖72%。非MenB菌株中,4CMenB的MenDeVAR预测交叉反应88%、未覆盖6%、数据不足6%;rLP2086-fHbp预测交叉反应12%、数据不足88%;gMATS预测非MenB总体覆盖50%。结论认为智利菌株遗传变异与其他国家不同,限制了现有工具对疫苗覆盖的预测。

要点

  • 42株儿童脑膜炎奈瑟菌以MenB(25株)和MenW(16株)为主,cc11和cc41/44最常见。
  • MenDeVAR预测4CMenB对MenB菌株完全匹配8%、交叉反应12%、未覆盖8%、数据不足64%。
  • gMATS预测4CMenB对MenB菌株覆盖16%、未覆盖8%、不可预测76%、总体覆盖54%。

核心结论

  • 智利菌株的遗传变异与其他国家不同,限制了gMATS和MenDeVAR等现有工具对疫苗覆盖的预测。

研究设计与样本

  • 对2016-2019年智利儿童患者分离的42株脑膜炎奈瑟菌进行全基因组测序,用BIGSdb平台分析基因组,并用MenDeVAR和gMATS工具预测疫苗覆盖。

主要发现

  • 42株中MenB 25株、MenW 16株、MenC 1株,cc11和cc41/44最常见。
  • PorA主要 deduced peptide 序列为P1.5,2(40%),肽P1.4存在于1株MenB;NHBA-29(64%),无菌株含肽2;fHbp-2(76%),1株含肽1,2株含肽45;NadA检出52%,肽6存在于84%,无菌株含肽8。
  • MenDeVAR预测MenB菌株对4CMenB完全匹配8%、交叉反应12%、未覆盖8%、数据不足64%;gMATS预测覆盖16%、未覆盖8%、不可预测76%、总体覆盖54%。
  • MenDeVAR预测MenB菌株对rLP2086-fHbp完全匹配8%、交叉反应64%、数据不足28%、总体覆盖72%。
  • 非MenB菌株中,MenDeVAR预测4CMenB交叉反应88%、未覆盖6%、数据不足6%;rLP2086-fHbp交叉反应12%、数据不足88%;gMATS预测非MenB总体覆盖50%。

关键数值与推荐

  • MenDeVAR预测MenB对4CMenB:完全匹配8%、交叉反应12%、未覆盖8%、数据不足64%。
  • gMATS预测MenB对4CMenB:覆盖16%、未覆盖8%、不可预测76%、总体覆盖54%。
  • MenDeVAR预测MenB对rLP2086-fHbp:完全匹配8%、交叉反应64%、数据不足28%、总体覆盖72%。
  • MenDeVAR预测非MenB对4CMenB:交叉反应88%、未覆盖6%、数据不足6%;对rLP2086-fHbp:交叉反应12%、数据不足88%。
  • gMATS预测非MenB总体覆盖50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Over the past few years, whole-genome sequencing (WGS) has become a valuable tool for global meningococcal surveillance. The objective of this study was to genetically characterize Neisseria meningitidis strains isolated from children in Chile through WGS and predicting potential vaccine coverage using gMATS and MenDeVAR. METHODS: WGS of 42 N.meningitidis from pediatric patients were processed and assembled using different software. We analyzed genomes with BIGSdb platform hosted at PubMLST.org, and predicted vaccine coverage using MenDeVAR and gMATS tools. RESULTS: Among 42 strains, 25 were MenB, 16 MenW, and 1 MenC. The cc11 and cc 41/44 were the most frequents. The main frequent deduced peptide sequence for PorA was P1.5,2 (40 %), peptide P1.4 was present in one MenB strain; NHBA-29 (64 %), none having peptide 2; fHbp-2 (76 %), one strain had peptide-1, and two had peptide 45; NadA was detected in 52 %, peptide-6 was present in 84 %, none had peptide 8. The MenDeVAR index predicted a coverage in MenB strains for 4CMenB 8 % exact matches, 12 % cross-reactivity, 8 % not coverage and 64 % had insufficient data. gMATS predicted 16 % was covered, 8 % not covered and 76 % unpredictable, and overall coverage of 54 %. For rLP2086-fHbp, the MenDeVAR index predicted exact match in 8 %, cross-reactivity in 64 %, and insufficient data in 28 % and an overall coverage of 72 %. In non-MenB strains, the MenDeVAR index predicted for 4CMenB vaccine: cross-reactivity 88 %, 6 % for not covered and insufficient data. For rLP2086-fHbp, predicted cross-reactivity 12 % and insufficient data in 88 %. gMATS predicted an overall coverage of 50 % for Non-MenB. CONCLUSION: genetic variability of the Chilean strains that its different from other countries, and until now limit the coverage prediction of vaccine with the available tools like gMATS and MenDeVAR.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Arteta-Acosta C, Villena R, Hormazabal JC, et al. Whole-genome sequencing of Neisseria meningitidis collected in Chile from pediatric patients during 2016-2019 and coverage vaccine prediction. Vaccine. 2024. PMID: 39276620. doi:10.1016/j.vaccine.2024.126311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。